Similarity in drugs: reflections on analogue design

Drug Discovery Today

Volumn 11, Issue 7-8, 2006, Pages 348-354

  Wermuth, Camille G ^a  

^a Prestwick Chemical Inc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 9 (2 HYDROXY 3 NONYL)ADENINE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BAZINAPRINE; BENZODIAZEPINE; BMS 192548; CAPTOPRIL; CHLORPROMAZINE; CIMETIDINE; CLOPIMOZIDE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMISOLE; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG ANALOG; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; ISOXAZOLE DERIVATIVE; LEVAMISOLE; MEVINOLIN; MIBEFRADIL; MINAPRINE; NEUROLEPTIC AGENT; PHOSPHODIESTERASE V INHIBITOR; TRANQUILIZER; UNINDEXED DRUG; ZAPRINAST; ZOLPIDEM; ZOPICLONE;

CHEMICAL STRUCTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; ERECTILE DYSFUNCTION; HUMAN; NATURAL SCIENCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; CHOLINERGIC ANTAGONISTS; COMPUTER-AIDED DESIGN; CYCLOOXYGENASE INHIBITORS; CYPROHEPTADINE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GABA ANTAGONISTS; HUMANS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PYRAZOLES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 33645855871     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.02.006     Document Type: Review

References (35)

1. Fischer, J. et al. (2005) Analogue-based drug discovery, IUPAC Project 2002-051-0-700
2. Fischer, J. and Ganellin, C.R. (eds) (2006) Analogue-based drug discovery, Wiley-VCH
3. Proudfoot J.R. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. 12 (2002) 1647-1650
4. Mandell G.L., and Petri Jr. W.A. Antimicrobial agents: penicillins, cephalosporins, and other β-lactam antibiotics. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics (1996), McGraw-Hill 1087-1102
5. Proudfoot, J.R. (2006) Drug likeness and analog based drug discovery. In Analog Based Drug Discovery (Fischer, J., Ganellin, C.R., eds), John Wiley-VCH
6. Hegde S., and Carter J. To market, to market. Ann. Rep. Med. Chem. 39 (2004) 337-368
7. Fischer J., and Gere A. Timing of analog research in drug discovery. Pharmazie 56 (2001) 675-682
8. Fischer J. Optimizing drug therapy by analogs. In: Fischer J., and Ganellin C.R. (Eds). Analog Based Drug Discovery (2005), John Wiley-VCH
9. Angell M. The truth about the drug companies: how they deceive us and what to do about It (2004), Random House
10. In: Rey A. (Ed). Dictionnaire Historique de la Langue Française (1992), Dictionnaires Le Robert
11. Duncan G.S., et al. Inhibition of lymphocytes-mediated-cytolysis and cyclic AMP phosphodiesterase by erythro-9-(2-hdroxy-3-nonyl)adenine. J. Immunopharmacol. 4 (1982) 79-100
12. Lugnier C., et al. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35 (1986) 1743-1751
13. Schueller F.W. Chemobiodynamics and Drug Design p. 405 (1960), McGraw-Hill Book Company, The Blakiston Division
14. Wermuth C.G. The Practice of Medicinal Chemistry (2003), Academic Press
15. Wermuth, C.G. (2006) Analogues as means of discovering new drugs. In Analog Based Drug Discovery (Fischer, J., Ganellin, C.R., eds), John Wiley-VCH
16. Bajorath J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Disc. 1 (2002) 882-894
17. Shu Y.Z., et al. BMS-192548, a tetracyclic binding inhibitor of neuropeptide Y receptors, from Aspergillus niger WB2346. II. Physico-chemical properties and structural characterization. J. Antibiot. 48 (1995) 1060-1065
18. Worms P., et al. SR 95191 a selective inhibitor of type A monoamine oxidase with dopaminergic properties I. Psychopharmacological profile in Rodents. J. Pharmacol. Exp. Ther. 240 (1987) 241-250
19. 2-adrenoceptor blocking activity. J. Med. Chem. 48 (2005) 2054-2071
20. Bullock M.W., et al. Resolution and racemization of dl-Tetramisole, dl-6-Phenyl-2,3,5,6-tetrahydroimidazo-[2,1-b]thiazole. J. Med. Chem. 11 (1968) 169-171
21. Schnieden H. Levamisole-a general pharmacological perspective. Int. J. Immunopharmacol. 3 (1981) 9-13
22. Remy D.C., et al. (+) and (-)-3-methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine. J. Med. Chem. 20 (1977) 1681-1684
23. Chambon J.-P., et al. An arylaminopyridazine derivative of γ-aminobutyric acid (GABA) is a selective and competitive antagonist at the GABAA receptor site. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 1832-1836
24. Wermuth C.G., and Bizière K. Pyridazinyl-GABA derivatives: a new class of synthetic GABA-A antagonists. Trends Pharmacol. Sci. 7 (1986) 421-424
25. Wermuth C.G., et al. Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of γ-aminobutyric acid acting as selective GABA-A antagonists. J. Med. Chem. 30 (1987) 239-249
26. Wermuth C.G. The development of pyridazinyl-GABA's, a new class of synthetic GABA antagonists. In: Ravina E. (Ed). Ist Spanish-Portuguese Congress of Therapeutical Chemistry (1987), Universidade de Santiago de Compostela 107-140
27. Wermuth C.G. Studies on the pyridazine series - pharmacological and therapeutic potential of 3-aminopyridazines. Actualités de Chimie Thérapeutique 12 (1985) 3-35
28. Rognan D., et al. Structure and molecular modeling of GABA-A receptor antagonists. J. Med. Chem. 35 (1992) 1969-1977
29. Jeanmart C., and Cotrel C. Synthèse de (chloro-5 pyridyl-2)-6 (méthyl-4 piperazinyl-1) carbonyloxy-5 oxo-7 dihydro-6,7 5H-pyrrolo[3-4b] pyrazine. Compt. Rend. Acad. Sci. Série C 287 (1978) 377-380
30. Doble A., et al. The pharmacology of cyclopyrrolone derivatives acting at the GABAA/benzodiazepine receptor. Adv. Biochem. Psychopharmacol. 47 (1992) 407-418
31. Arbilla S., et al. Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats. Naunyn Schmiedebergs Arch. Pharmacol. 330 (1985) 248-251
32. Schneider G., et al. 'Scaffold-hopping' by topological pharmacophore search: a contribution to virtual screening. Angew. Chem. Int. Ed. Engl. 38 (1999) 2894-2896
33. Kubinyi H., and Müller G. Chemogenomics in Drug Discovery (2004), Wiley-VCH
34. Janssen P.A.J., and Van der Eycken C.A.M. The chemical anatomy of potent morphine-like analgesics. In: Burger A. (Ed). Drugs Affecting the Central Nervous system (1968), Marcel Dekker 25-60
35. Böhm H.-J., et al. Scaffold hopping. Drug Discov. Today Tech. 1 (2004) 217-224